**COMPANY REGISTRATION NUMBER: 08032149**
## **CHARITY REGISTRATION NUMBER: 1150449**
## **Drugscience Ltd**
**Company Limited by Guarantee Unaudited Financial Statements 30 June 2025**
## **BURGESS HODGSON LIMITED**
Camburgh House 27 New Dover Road Canterbury Kent CT1 3DN
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Financial Statements**
## **Year ended 30 June 2025**
||**Page**|
|---|---|
|Trustees' annual report (incorporating the director's report)|**1**|
|Independent examiner's report to the trustees|**5**|
|Statement of financial activities (including income and||
|expenditure account)|**6**|
|Statement of financial position|**7**|
|Notes to the financial statements|**8**|
**Drugscience Ltd**
## **Company Limited by Guarantee**
## **Trustees' Annual Report (Incorporating the Director's Report)**
## **Year ended 30 June 2025**
The trustees, who are also the directors for the purposes of company law, present their report and the unaudited financial statements of the charity for the year ended 30 June 2025.
## **Reference and administrative details**
**Registered charity name** Drugscience Ltd **Charity registration number** 1150449 **Company registration number** 08032149 **Principal office and registered** Camburgh House **office** 27 New Dover Road Canterbury Kent CT1 3DN United Kingdom
## **The trustees**
Countess D E Ashley-Cooper Prof I Crome (Resigned 1 December 2024) A D Knight (Resigned 1 April 2025) Prof D J Nutt J Smith Prof J Nuttall (Appointed 1 January 2025) R Velarde
The trustees present their annual report together with the financial statements of Drugscience Ltd ('the charity') for the year ended 30 June 2025.
## **Company secretary**
**Independent examiner**
S P Macken Burgess Hodgson Limited Camburgh House 27 New Dover Road Canterbury Kent CT1 3DN
**- 1 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
**Trustees' Annual Report (Incorporating the Director's Report)** _**(continued)**_
## **Year ended 30 June 2025**
## **Structure, governance and management**
## **Constitution**
The charity is constituted under a Memorandum of Association dated 16 April 2012 and amended by a Special Resolution dated 17 December 2012. It is a registered charity with its charity number being 1150449.
The charity is limited by guarantee and does not have share capital. All trustees are members of the charity and guarantee to contribute £1 in the event of winding up.
## **Appointment of trustees**
The trustees have complete control of the charity in relation to the application of funds. Trustees are appointed in accordance with the charity's governing document. All decision making of Drugscience is made in accordance with the charity's Conflicts of Interest policy.
## **Trustees**
The trustees who served during the year were: Prof Ilana B Crome (Chair) Mr A D Knight Prof D Nutt Dr D Shaftesbury. Mr J Smith
## **Objectives and activities**
## **Policies and objectives**
The principal objectives of the charity are:
To advance the education of the public in the harms of drug taking to help prevent and mitigate the suffering caused by drug harms and associated behaviours;
To promote good health of the general public by providing advice tp the public and practitioners who are impacted by drug taking in anyway by providing advice to the public and practitioners; and
To promote research for the benefit of the public, in the subject of drugs and drug taking and into its effects on the public and society in general, whether physical, medical, psychological or social.
## **Public benefit statement**
The trustees have given due consideration the Charity Commission published guidance on the public benefit requirements. The charity constitutes a public benefit entity as defined by FRS 102.
**- 2 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Trustees' Annual Report (Incorporating the Director's Report)** _**(continued)**_
## **Year ended 30 June 2025**
## **Achievements and performance**
The charity has a vital role to play in society, providing the public in the UK and internationally with high quality, scientifically based information on drugs and evidence based comment and analysis of new research. The charity aims to inform the public understanding about drugs and promote effective policies and practice in the UK and at the international level.
The charity reviews and investigates the scientific evidence relating to drugs, free from political concerns. The charity provides accessible information on drugs to the public and professionals via direct communication, podcasts, educational resources, webinars, events and via its web-based information pages. The charity works in the UK and internationally and addresses issues surrounding drug harms and benefits; regulation and education; prevention, treatment and recovery.
## We believe that:
Everyone has the right to be able to access accurate information about the effects, harms and benefits of drugs.
- All people have the right to receive effective, evidence-based drug education.
- All people with drug-related problems have the right to services that will support their recovery.
- There needs to be an ongoing and open public discussion about drugs and their place within our
- society.
- Policy and practice should be based on evidence from research, experience and independent
- review.
- All drug users have the right to a life free from discrimination and stigma.
- Any regulation of drug use should aim to prevent and reduce the harmful consequences of drug
- use. It should be proportionate to the harms.
- It is vitally important to extend the evidence base on drugs through research.
- Public services should aim to prevent and reduce harms to drug users and others.
- Unnecessary and overly laborious barriers to research should be eroded to facilitate a higher
- quality understanding of drugs regardless of their legal status.
## **Trustee meetings**
The charity trustee meetings were held every two months throughout this period. The main issues discussed included:
- Governance and organisational structure
- Accountancy
- Debt collection
- Fundraising
**- 3 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Trustees' Annual Report (Incorporating the Director's Report)** _**(continued)**_
## **Year ended 30 June 2025**
- Drug Science strategy
- Progress reports
- Research progress
## **Financial review**
## **Result for the vear**
The results for the year are shown in the statement of the financial activities on page 15. During the year, the charity received donations and other income totalling of £380,127 (2024: £704,900). The cost of raising funds for the period (including allocated support costs) totalled £149,888 (2024: £153,428). Expenditure on charitable activities of £485,634 (2024: £414,854) brought total expenditure for the year to £635,522 (2024: £568,282). The result for the year ended 30 June 2025 was a deficit of of £255,395 (surplus 2024: £136,618). The balance of the unrestricted reserves as at 30 June 2025 was £545,205 (2024: £609,537) and restricted reserves £146,803 (2024: £337,866).
## **Reserves policy**
The level of reserves is monitored and reviewed by the trustees at least annually. The trustees believe that the charity should target to hold unrestricted financial reserves equivalent to a minimum of 2 year's core costs. This is estimated to be £160,000.
## **Plans for future periods**
The priority for the charity continues to be to secure financial stability. Whilst the income generated has been helpful to support this aims and to further raise the profile of the charity, we are still working on developing funding avenues not dependent on a particular sector alone. The key aim for the foreseeable future is to fully develop financial sustainability, ensuring that its income is sufficient to allow the organisation to continue to meet its charitable objectives.
## **Small company provisions**
This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
The trustees' annual report was approved on 12th May 2026 and signed on behalf of the board of trustees by:
Prof J Nuttall Trustee
**- 4 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Independent Examiner's Report to the Trustees of Drugscience Ltd**
## **Year ended 30 June 2025**
I report to the trustees on my examination of the financial statements of Drugscience Ltd ('the charity') for the year ended 30 June 2025.
## **Responsibilities and basis of report**
As the trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act’).
Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity’s accounts as carried out under section 145 of the Charities Act 2011 (‘the 2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.
## **Independent examiner's statement**
Since the charity’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales (ICAEW), which is one of the listed bodies.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a ‘true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Burgess Hodgson Limited Independent Examiner
Camburgh House 27 New Dover Road Canterbury Kent CT1 3DN
**- 5 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Statement of Financial Activities (including income and expenditure account)**
## **Year ended 30 June 2025**
||||**2025**||2024|
|---|---|---|---|---|---|
|||Unrestricted|Restricted|||
|||funds|funds|**Total funds**|Total funds|
||**Note**|**£**|**£**|**£**|£|
|**Income and endowments**||||||
|Donations and legacies|**5**|158,515|158,275|316,790|401,618|
|Charitable activities|**6**|20,758|31,416|52,174|303,282|
|Investment income|**7**|1,073|10,090|11,163|–|
|||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
|**Total income**||180,346|199,781|380,127|704,900|
|||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
|**Expenditure**||||||
|Expenditure on raising funds:||||||
|Costs of raising donations and||||||
|legacies|**8**|42,519|107,369|149,888|153,428|
|Expenditure on charitable activities|**9,10**|202,159|283,475|485,634|414,854|
|||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
|**Total expenditure**||244,678|390,844|635,522|568,282|
|||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
|||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
|**Net (expenditure)/income and net**||||||
|**movement in funds**||(64,332)|(191,063)|(255,395)|136,618|
|||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
|**Reconciliation of funds**||||||
|Total funds brought forward||609,537|337,866|947,403|810,785|
|||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
|**Total funds carried forward**||545,205|146,803|692,008|947,403|
|||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.
**The notes on pages 8 to 16 form part of these financial statements.**
**- 6 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Statement of Financial Position**
## **30 June 2025**
|||**2025**|2024|
|---|---|---|---|
||**Note**|**£**|£|
|**Fixed assets**||||
|Investments|**16**|1|1|
|**Current assets**||||
|Debtors|**17**|429,298|651,378|
|Cash at bank and in hand||288,921|505,224|
|||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄৄৄৄ|
|||718,219|1,156,602|
|**Creditors: amounts falling due within one year**|**18**|26,212|209,200|
|||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄৄৄৄ|
|**Net current assets**||692,007|947,402|
|||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
|**Total assets less current liabilities**||692,008|947,403|
|||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
|**Net assets**||692,008|947,403|
|||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
|**Funds of the charity**||||
|Restricted funds||146,803|337,866|
|Unrestricted funds||545,205|609,537|
|||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
|**Total charity funds**|**21**|692,008|947,403|
|||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
For the year ending 30 June 2025 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.
These financial statements were approved by the board of trustees and authorised for issue on ........................, and are signed on behalf of the board by:
Prof J Nuttall Trustee
**The notes on pages 8 to 16 form part of these financial statements.**
**- 7 -**
**Drugscience Ltd**
## **Company Limited by Guarantee**
## **Notes to the Financial Statements**
## **Year ended 30 June 2025**
## **1. General information**
The charity is a public benefit entity and a private company limited by guarantee, registered in England and Wales and a registered charity in England and Wales. The address of the registered office is Camburgh House, 27 New Dover Road, Canterbury, Kent, CT1 3DN, United Kingdom.
## **2. Statement of compliance**
These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Companies Act 2006.
## **3. Accounting policies**
## **Basis of preparation**
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through income or expenditure.
The financial statements are prepared in sterling, which is the functional currency of the entity.
## **Going concern**
There are no material uncertainties about the charity's ability to continue.
## **Judgements and key sources of estimation uncertainty**
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
## **Foreign currencies**
Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the statement of financial activities.
## **Fund accounting**
Unrestricted funds are available for use at the discretion of the trustees to further any of the charity's purposes.
Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment.
Restricted funds are subjected to restrictions on their expenditure declared by the donor or through the terms of an appeal, and fall into one of two sub-classes: restricted income funds or endowment funds.
**- 8 -**
**Drugscience Ltd**
## **Company Limited by Guarantee**
## **Notes to the Financial Statements** _**(continued)**_
## **Year ended 30 June 2025**
**3. Accounting policies** _**(continued)**_
## **Incoming resources**
All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income:
- income from donations or grants is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably.
- legacy income is recognised when receipt is probable and entitlement is established.
- income from donated goods is measured at the fair value of the goods unless this is impractical to measure reliably, in which case the value is derived from the cost to the donor or the estimated resale value. Donated facilities and services are recognised in the accounts when received if the value can be reliably measured. No amounts are included for the contribution of general volunteers.
- income from contracts for the supply of services is recognised with the delivery of the contracted service. This is classified as unrestricted funds unless there is a contractual requirement for it to be spent on a particular purpose and returned if unspent, in which case it may be regarded as restricted.
## **Resources expended**
Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates:
- expenditure on raising funds includes the costs of all fundraising activities, events, noncharitable trading activities, and the sale of donated goods.
- expenditure on charitable activities includes all costs incurred by a charity in undertaking activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities.
- other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities.
All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis.
## **Investments**
Unlisted equity investments are initially recorded at cost, and subsequently measured at fair value. If fair value cannot be reliably measured, assets are measured at cost less impairment.
Listed investments are measured at fair value with changes in fair value being recognised in income or expenditure.
**- 9 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Notes to the Financial Statements** _**(continued)**_
## **Year ended 30 June 2025**
## **3. Accounting policies** _**(continued)**_
## **Impairment of fixed assets**
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recover-able amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible re-versal at each reporting date.
## **Financial instruments**
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into.
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.
Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value.
## **Defined contribution plans**
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.
## **4. Limited by guarantee**
Every member of the company undertakes to contribute a sum not exceeding £1 to the assets of the company if it is wound up during his, her or its membership or within one year afterwards:
(a) for payment of the debts and liabilities of the company contracted before he, she or it ceased to be a member;
(b) for the costs, charges and expenses of winding up; and
(c) for the adjustment of the rights of the contributories among themselves.
## **5. Donations and legacies**
||Unrestricted|Restricted|**Total Funds**|
|---|---|---|---|
||Funds|Funds|**2025**|
||£|£|**£**|
|**Donations**||||
|Donations|158,515|13,416|171,931|
|**Grants**||||
|Grants receivable|–|144,859|144,859|
||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
||158,515|158,275|316,790|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
**- 10 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Notes to the Financial Statements** _**(continued)**_
## **Year ended 30 June 2025**
## **5. Donations and legacies** _**(continued)**_
||Unrestricted|Restricted|Total Funds|
|---|---|---|---|
||Funds|Funds|2024|
||£|£|£|
|**Donations**||||
|Donations|43,521|59,842|103,363|
|**Grants**||||
|Grants receivable|–|298,255|298,255|
||ৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
||43,521|358,097|401,618|
||৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
## **6. Charitable activities**
||Unrestricted|Restricted|**Total Funds**|
|---|---|---|---|
||Funds|Funds|**2025**|
||£|£|**£**|
|Non-profit income|17,160|31,624|48,784|
|Book royalties|716|–|716|
|Events|2,882|(208)|2,674|
||ৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄ|
||20,758|31,416|52,174|
||৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶|
||Unrestricted|Restricted|Total Funds|
||Funds|Funds|2024|
||£|£|£|
|Non-profit income|274,717|(1,250)|273,467|
|Book royalties|4,982|–|4,982|
|Events|4,851|19,982|24,833|
||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
||284,550|18,732|303,282|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
## **7. Investment income**
||Unrestricted|Restricted|**Total Funds**|
|---|---|---|---|
||Funds|Funds|**2025**|
||£|£|**£**|
|Other interest receivable|1,073|–|1,073|
|Investments|–|10,090|10,090|
||ৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄ|
||1,073|10,090|11,163|
||৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶|
||Unrestricted|Restricted|Total Funds|
||Funds|Funds|2024|
||£|£|£|
|Other interest receivable|–|–|–|
|Investments|–|–|–|
||ৄৄৄৄ|ৄৄৄৄ|ৄৄৄৄ|
||–|–|–|
||৶৶৶৶|৶৶৶৶|৶৶৶৶|
**- 11 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Notes to the Financial Statements** _**(continued)**_
## **Year ended 30 June 2025**
## **8. Costs of raising donations and legacies**
||Unrestricted|Restricted|**Total Funds**|
|---|---|---|---|
||Funds|Funds|**2025**|
||£|£|**£**|
|Allocated support costs|38,103|4,626|42,729|
|Costs of raising donations and legacies|2,500|102,423|104,923|
|Marketing|1,916|320|2,236|
|PR/Public income|–|–|–|
||ৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
||42,519|107,369|149,888|
||৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
||Unrestricted|Restricted|Total Funds|
||Funds|Funds|2024|
||£|£|£|
|Allocated support costs|101,991|41,572|143,563|
|Costs of raising donations and legacies|–|–|–|
|Marketing|528|6,837|7,365|
|PR/Public income|2,500|–|2,500|
||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
||105,019|48,409|153,428|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
|**Expenditure on charitable activities by fund type**||||
||Unrestricted|Restricted|**Total Funds**|
||Funds|Funds|**2025**|
||£|£|**£**|
|Support costs|202,159|283,475|485,634|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
||Unrestricted|Restricted|Total Funds|
||Funds|Funds|2024|
||£|£|£|
|Support costs|111,362|303,492|414,854|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
|**Expenditure on charitable activities by activity type**||||
|||**Total funds**|Total fund|
||Support costs|**2025**|2024|
||£|**£**|£|
|Staff costs|215,839|215,839|225,319|
|Governance costs|269,795|269,795|189,535|
||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
||485,634|485,634|414,854|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
## **9. Expenditure on charitable activities by fund type**
## **10. Expenditure on charitable activities by activity type**
**- 12 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Notes to the Financial Statements** _**(continued)**_
## **Year ended 30 June 2025**
## **11. Analysis of support costs**
|||Charitable|Charitable|||
|---|---|---|---|---|---|
|||activities||**Total 2025**|Total 2024|
||||£|**£**|£|
||Staff costs|213,278||213,278|306,683|
||Communications and IT||–|–|72,334|
||Finance costs||2,561|2,561|–|
||Governance costs|278,994||278,994|189,535|
||||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
|||494,833||494,833|568,552|
||||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
|**12.**|**Net (expenditure)/income**|||||
||Net (expenditure)/income is stated after charging/(crediting):|||||
|||||**2025**|2024|
|||||**£**|£|
||Foreign exchange differences|||2,561|9,007|
|||||৶৶৶৶৶৶৶|৶৶৶৶৶৶৶|
|**13.**|**Independent examination fees**|||||
|||||**2025**|2024|
|||||**£**|£|
||Fees payable to the independent examiner for:|||||
||Independent examination of the financial statements|||1,500|1,850|
|||||৶৶৶৶৶৶৶|৶৶৶৶৶৶৶|
|**14.**|**Staff costs**|||||
||The total staff costs and employee benefits for the reporting period are analysed as||||follows:|
|||||**2025**|2024|
|||||**£**|£|
||Wages and salaries|||175,721|234,841|
||Social security costs|||8,139|14,380|
||Employer contributions to pension plans|||2,226|3,435|
||Other employee benefits|||–|32,670|
|||||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
|||||186,086|285,326|
|||||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
||The average head count of employees during the year was||3 (2024: 5). The average number of|||
||full-time equivalent employees during the year is analysed as follows:|||||
|||||**2025**|2024|
|||||**No.**|No.|
||Number of staff|||3|5|
|||||৶৶৶৶|৶৶৶৶|
||The number of employees whose remuneration for the year fell within the following||||bands, were:|
|||||**2025**|2024|
|||||**No.**|No.|
||£60,000 to £69,999|||1|1|
|||||৶৶৶৶|৶৶৶৶|
**- 13 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Notes to the Financial Statements** _**(continued)**_
## **Year ended 30 June 2025**
## **15. Trustee remuneration and expenses**
No trustees received any emoluments or reimbursement of out of pocket expenses for their services as trustees during the year (2024: none).
## **16. Investments**
||**Other**|
|---|---|
||**investments**|
||**£**|
|**Cost or valuation**||
|At 1 July 2024|1|
|Additions|–|
||ৄৄৄৄ|
|**At 30 June 2025**|1|
||৶৶৶৶|
|**Impairment**||
|**At 1 July 2024 and 30 June 2025**|–|
||৶৶৶৶|
|**Carrying amount**||
|**At 30 June 2025**|1|
||৶৶৶৶|
|At 30 June 2024|1|
||৶৶৶৶|
All investments shown above are held at valuation.
## **17. Debtors**
||**2025**|2024|
|---|---|---|
||**£**|£|
|Trade debtors|4,430|151,672|
|Amounts owed by group undertakings|420,837|499,471|
|Other debtors|4,031|235|
||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
||429,298|651,378|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
|**Creditors:** **amounts falling due within one year**|||
||**2025**|2024|
||**£**|£|
|Trade creditors|12,811|89,192|
|Accruals and deferred income|4,350|42,275|
|Corporation tax|–|73,542|
|Social security and other taxes|9,051|4,191|
||ৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
||26,212|209,200|
||৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
|**Deferred income**|||
||**2025**|2024|
||**£**|£|
|At 1 July 2024|–|36,958|
||৶৶৶৶|৶৶৶৶৶৶৶৶|
## **18. Creditors: amounts falling due within one year**
## **19. Deferred income**
**- 14 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Notes to the Financial Statements** _**(continued)**_
## **Year ended 30 June 2025**
## **20. Pensions and other post retirement benefits**
## **Defined contribution plans**
The amount recognised in income or expenditure as an expense in relation to defined contribution plans was £2,226 (2024: £3,435).
## **21. Analysis of charitable funds**
## **Unrestricted funds**
|**Unrestricted funds**||||||
|---|---|---|---|---|---|
||||||**At**|
||At 1 July 2024|Income|Expenditure|**30 June 2025**||
||£|£|£||£|
|General funds|609,537|180,346|(244,678)||545,205|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶||৶৶৶৶৶৶৶৶৶|
||||||At|
||At 1 July 2023|Income|Expenditure||30 June 2024|
||£|£|£||£|
|General funds|497,847|328,071|(216,381)||609,537|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶||৶৶৶৶৶৶৶৶৶|
|**Restricted funds**||||||
||||||**At**|
||At 1 July 2024|Income|Expenditure|**30 June 2025**||
||£|£|£||£|
|Twenty21 (a)|153,424|16,550|(169,974)||–|
|PAREA (b)|48,771|17,173|(65,944)||–|
|Long covid (c)|–|–|–||–|
|MPWG (d)|135,671|166,058|(154,926)||146,803|
||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ||ৄৄৄৄৄৄৄৄৄ|
||337,866|199,781|(390,844)||146,803|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶||৶৶৶৶৶৶৶৶৶|
||||||At|
||At 1 July 2023|Income|Expenditure||30 June 2024|
||£|£|£||£|
|Twenty21 (a)|319,931|2,542|(169,049)||153,424|
|PAREA (b)|14,332|153,397|(118,958)||48,771|
|Long covid (c)|(21,325)|16,325|5,000||–|
|MPWG (d)|–|204,565|(68,894)||135,671|
||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ||ৄৄৄৄৄৄৄৄৄ|
||312,938
৶৶৶৶৶৶৶৶৶|376,829
৶৶৶৶৶৶৶৶৶|(351,901)
৶৶৶৶৶৶৶৶৶||337,866
৶৶৶৶৶৶৶৶৶|
**- 15 -**
## **Drugscience Ltd**
## **Company Limited by Guarantee**
## **Notes to the Financial Statements** _**(continued)**_
## **Year ended 30 June 2025**
## **22. Analysis of net assets between funds**
||Unrestricted|Restricted|**Total Funds**|
|---|---|---|---|
||Funds|Funds|**2025**|
||£|£|**£**|
|Investments|–|1|1|
|Current assets|562,218|146,802|709,020|
|Creditors less than 1 year|(26,212)|–|(26,212)|
||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|
|**Net assets**|536,006|146,803|682,809|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|
||Unrestricted|Restricted|Total Funds|
||Funds|Funds|2024|
||£|£|£|
|Investments|–|1|1|
|Current assets|818,737|337,865|1,156,602|
|Creditors less than 1 year|(209,200)|–|(209,200)|
||ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄ|ৄৄৄৄৄৄৄৄৄৄৄৄ|
|**Net assets**|609,537|337,866|947,403|
||৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶|৶৶৶৶৶৶৶৶৶৶৶৶|
**- 16 -**